TC
ICPT

TFS Capital’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

TFS Capital’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-6,418
Closed -$438K – 1630
2013
Q4 		$438K Sell
6,418
-6,287
-49% -$363K 0.02% 882
2013
Q3 		$877K Buy
12,705
+457
+4% +$22.6K 0.04% 632
2013
Q2 		$549K Buy
+12,248
New +$418K 0.02% 862

Other funds holding ICPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

TFS Capital's ICPT Position: Q1 2014 in Review

TFS Capital sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q1 2014, closing a stake of 6,418 shares — an estimated $438K sold.

TFS Capital first reported a position in ICPT in Q2 2013 and held it in 3 quarters. The position peaked at $877K in Q3 2013. 172 funds tracked by Wall St. Rank hold ICPT as of Q1 2014.

  • TFS Capital reported no remaining Intercept Pharmaceuticals, Inc. position as of Q1 2014 after selling out during the quarter.
  • TFS Capital sold 6,418 Intercept Pharmaceuticals, Inc. shares in Q1 2014, an estimated $438K.
  • TFS Capital first reported a position in Intercept Pharmaceuticals, Inc. in Q2 2013 and held it in 3 quarters.
  • TFS Capital's Intercept Pharmaceuticals, Inc. position peaked at $877K in Q3 2013.
  • 172 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q1 2014.

Based on TFS Capital's 13F filing for Q1 2014, filed 5 May 2014.